| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 10%+ Owner | $5,202,170 | 23 Dec 2024 | ||
| Steve Elms | Director | $1,050,682 | 17 Nov 2025 | ||
| Peter L. Hoang | President and CEO, Director | $234,297 | 24 Mar 2022 | ||
| Anthony H. Kim | Chief Financial Officer | $55,479 | 24 Mar 2022 | ||
| Frederick G. Wasserman | Director | $31,620 | 08 Jun 2021 | ||
| Anna Szymanska | Vice President, Quality | 27 Feb 2023 | |||
| Nadia Agopyan | SVP, Regulatory Affairs | 27 Feb 2023 | |||
| Michael Loiacono | Chief Accounting Officer | 27 Feb 2023 | |||
| Gerald Garrett | Vice President, Clinical Ops. | 17 Feb 2022 | |||
| Mythili Koneru | Chief Medical Officer | 27 Feb 2023 | |||
| Katharine Knobil | Director | 17 Nov 2025 | |||
| John R. Wilson | Director | 06 Jun 2023 | |||
| Eliot M. Lurier | Interim CFO | 30 Jun 2023 | |||
| Kathryn Penkus Corzo | Director | 31 Oct 2025 | |||
| Tsvetelina P. Hoang | VP, Research and Development | 27 Feb 2023 | |||
| Juan Vera | Chief Executive Officer, Director | 31 Oct 2025 | |||
| Norman David Eansor | Director | 17 Nov 2025 | |||
| David Laskow-Pooley | Director | 24 May 2022 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Katharine Knobil | MRKR | Stock Option (Right to Buy) | Award | 221,741 | 137,330 | 17 Nov 2025 | Direct | |||
| Norman David Eansor | MRKR | Stock Option (Right to Buy) | Award | 221,741 | 137,330 | 17 Nov 2025 | Direct | |||
| Steve Elms | MRKR | Stock Option (right to buy) | Award | 221,741 | 137,330 | 17 Nov 2025 | Direct | |||
| Kathryn Penkus Corzo | MRKR | Stock Option (Right to Buy) | Award | 147,611 | 147,611 | 31 Oct 2025 | Direct | |||
| Juan Vera | MRKR | Employee Stock Option (right to buy) | Award | 250,000 | 250,000 | 31 Oct 2025 | Direct |